Pfizer Inc. (NYSE:PFE) Shares Purchased by Skandinaviska Enskilda Banken AB publ

Key Points

• Skandinaviska Enskilda Banken AB publ increased its holdings in Pfizer by 3.0%, owning over 1.17 million shares valued at approximately $29.67 million.
• Pfizer reported a Q1 EPS of $0.92, exceeding analysts' expectations, although their revenue decreased by 7.8% year-over-year.
• The company recently announced a quarterly dividend of $0.43, representing an annualized dividend yield of 6.94% with a payout ratio of 124.64%.

Skandinaviska Enskilda Banken AB publ increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 3.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,172,299 shares of the biopharmaceutical company's stock after acquiring an additional 33,762 shares during the period. Skandinaviska Enskilda Banken AB publ's holdings in Pfizer were worth $29,671,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the company. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer in the 4th quarter worth about $27,000. Gould Capital LLC boosted its position in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares in the last quarter. North Capital Inc. purchased a new stake in shares of Pfizer in the 1st quarter worth about $28,000. Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer in the 4th quarter worth about $30,000. Finally, Horizon Financial Services LLC purchased a new stake in shares of Pfizer in the 1st quarter worth about $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Pfizer stock opened at $24.79 on Friday. The stock's 50-day moving average is $24.30 and its 200-day moving average is $24.68. The company has a market cap of $140.91 billion, a price-to-earnings ratio of 17.96, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period last year, the business posted $0.82 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.94%. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on PFE shares. Jefferies Financial Group upped their price objective on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. TD Cowen reduced their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research report on Tuesday, April 22nd. HSBC reduced their price objective on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Finally, Wolfe Research upped their price objective on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.